- Home
- AUDC vs ELDN Comparison
AUDC vs ELDN Comparison
Compare AUDC & ELDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUDC
- ELDN
- Stock Information
- Founded
- AUDC 1992
- ELDN 2004
- Country
- AUDC Israel
- ELDN United States
- Employees
- AUDC N/A
- ELDN N/A
- Industry
- AUDC Telecommunications Equipment
- ELDN Biotechnology: Pharmaceutical Preparations
- Sector
- AUDC Utilities
- ELDN Health Care
- Exchange
- AUDC Nasdaq
- ELDN Nasdaq
- Market Cap
- AUDC 267.1M
- ELDN 239.6M
- IPO Year
- AUDC 1999
- ELDN N/A
- Fundamental
- Price
- AUDC $8.95
- ELDN $4.12
- Analyst Decision
- AUDC Buy
- ELDN Strong Buy
- Analyst Count
- AUDC 2
- ELDN 1
- Target Price
- AUDC $10.00
- ELDN $16.00
- AVG Volume (30 Days)
- AUDC 67.5K
- ELDN 423.5K
- Earning Date
- AUDC 02-04-2025
- ELDN 11-12-2024
- Dividend Yield
- AUDC 3.92%
- ELDN N/A
- EPS Growth
- AUDC 0.25
- ELDN N/A
- EPS
- AUDC 0.40
- ELDN N/A
- Revenue
- AUDC $244,181,000.00
- ELDN N/A
- Revenue This Year
- AUDC $1.06
- ELDN N/A
- Revenue Next Year
- AUDC $2.94
- ELDN N/A
- P/E Ratio
- AUDC $22.91
- ELDN N/A
- Revenue Growth
- AUDC N/A
- ELDN N/A
- 52 Week Low
- AUDC $7.70
- ELDN $1.43
- 52 Week High
- AUDC $14.45
- ELDN $5.54
- Technical
- Relative Strength Index (RSI)
- AUDC 44.45
- ELDN 50.60
- Support Level
- AUDC $9.13
- ELDN $4.32
- Resistance Level
- AUDC $9.85
- ELDN $4.76
- Average True Range (ATR)
- AUDC 0.25
- ELDN 0.40
- MACD
- AUDC -0.03
- ELDN -0.05
- Stochastic Oscillator
- AUDC 0.00
- ELDN 26.06
About AUDC AudioCodes Ltd.
AudioCodes Ltd develops and sells advanced and converged voice over IP and data networking solutions, products and applications to service providers and channels, OEMs, network equipment providers and system integrators. Its products include IP phones, session border controllers, voice applications, multi-service business routers, digital and analog media gateways, among others. The company generates revenues from the sale of products through a direct sales force and sales representatives. Its geographic segments are Israel, Americas, Europe, and the Far East. It derives a majority of the revenues from Americas segment.
About ELDN Eledon Pharmaceuticals Inc.
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.